X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
Imara is advancing tovinontrine (IMR-687), a highly-selective, potent small molecule inhibitor of PDE9 that is an oral, potentially disease-modifying treatment currently in clinical development for SCD and beta-thalassemia and preclinical development for HFpEF.
Lead Product(s): Tovinontrine
Therapeutic Area: Cardiology/Vascular Diseases Product Name: IMR-687
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 08, 2021
Details:
The VOC data in our 93-patient Phase 2a clinical trial point to a potential multimodal mechanism-of-action of IMR-687 in sickle cell disease that acts primarily on red blood cells and has the potential to act on white blood cells, adhesion mediators and other cell types.
Lead Product(s): Tovinontrine
Therapeutic Area: Genetic Disease Product Name: IMR-687
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 11, 2021
Details:
Biomarker data from both monotherapy IMR-687 and combination IMR-687+HU groups show improvement in markers of hemolysis with variable HbF results.
Lead Product(s): Tovinontrine
Therapeutic Area: Genetic Disease Product Name: IMR-687
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 06, 2021
Details:
Forte is the first clinical trial of IMR-687 in patients with beta-thalassemia and follows the initiation of Ardent Phase 2b clinical trial of IMR-687 in sickle cell disease.
Lead Product(s): Tovinontrine
Therapeutic Area: Genetic Disease Product Name: IMR-687
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 16, 2020
Details:
IMR-687 has previously been granted Orphan Drug, Fast Track and Rare Pediatric Disease designations from the U.S. Food and Drug Administration (FDA) for the treatment of patients with SCD.
Lead Product(s): Tovinontrine
Therapeutic Area: Genetic Disease Product Name: IMR-687
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 25, 2020
Details:
IMR-687 has demonstrated the potential to directly and selectively inhibit PDE9 and may offer distinct advantages over other therapies, including fetal hemoglobin induction, a multimodal mechanism and a once daily oral dosing regimen.
Lead Product(s): Tovinontrine
Therapeutic Area: Genetic Disease Product Name: IMR-687
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 13, 2020
Details:
Imara recently initiated a Phase 2b clinical trial of IMR-687 in adult patients with beta-thalassemia and expects to dose the first patient in the near-term.
Lead Product(s): Tovinontrine
Therapeutic Area: Genetic Disease Product Name: IMR-687
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 30, 2020
Details:
The U.S. FDA has granted Orphan Drug Designation for IMR-687 for the treatment of patients with beta-thalassemia. The FDA previously granted Orphan Drug Designation for IMR-687 for the treatment of patients with sickle cell disease.
Lead Product(s): Tovinontrine
Therapeutic Area: Genetic Disease Product Name: IMR-687
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 24, 2020
Details:
IMR-687 showed statistically significant increase in red blood cells containing fetal hemoglobin (F-cells) and dose-dependent increase in fetal hemoglobin percentage in high-dose group after 24 weeks of monotherapy.
Lead Product(s): Tovinontrine
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 12, 2020
Details:
Imara will present interim data from the ongoing Phase 2a study of IMR-687 in patients with sickle cell disease at the 25th Annual European Hematology Association (EHA) Congress. Imara completed enrollment in the IMR-687 Phase 2a clinical trial in sickle cell patients.
Lead Product(s): Tovinontrine
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 21, 2020
Details:
PO cash will support Imara to continue its research on drugs for rare blood conditions with Its lead compound, IMR-687.
Lead Product(s): Tovinontrine
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $75.2 million Upfront Cash: Undisclosed
Deal Type: Public Offering March 12, 2020
Details:
The capital received from the proceed will help company to advance of its own sickle cell drug, IMR-687.
Lead Product(s): Tovinontrine
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $86.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering February 18, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
